Literature DB >> 23436269

Population pharmacokinetic modeling of sertraline treatment in patients with Alzheimer disease: the DIADS-2 study.

Claire H Li1, Bruce G Pollock, Constantine G Lyketsos, Vijay Vaidya, Lea T Drye, Margaret Kirshner, Denise Sorisio, Robert R Bies.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23436269      PMCID： PMC3604147          DOI： 10.1177/0091270012445793

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN： 0091-2700            Impact factor:   3.126


× No keyword cloud information.
  18 in total

1.  Comparison of the effects of sertraline and its metabolite desmethylsertraline on blockade of central 5-HT reuptake in vivo.

Authors:  J Sprouse; T Clarke; L Reynolds; J Heym; H Rollema
Journal:  Neuropsychopharmacology       Date:  1996-04       Impact factor: 7.853

2.  Sertraline N-demethylation is catalyzed by multiple isoforms of human cytochrome P-450 in vitro.

Authors:  K Kobayashi; T Ishizuka; N Shimada; Y Yoshimura; K Kamijima; K Chiba
Journal:  Drug Metab Dispos       Date:  1999-07       Impact factor: 3.922

3.  Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers.

Authors:  R A Ronfeld; L M Tremaine; K D Wilner
Journal:  Clin Pharmacokinet       Date:  1997       Impact factor: 6.447

4.  Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites.

Authors:  M J Owens; W N Morgan; S J Plott; C B Nemeroff
Journal:  J Pharmacol Exp Ther       Date:  1997-12       Impact factor: 4.030

Review 5.  Pharmacokinetics of selective serotonin reuptake inhibitors.

Authors:  C Hiemke; S Härtter
Journal:  Pharmacol Ther       Date:  2000-01       Impact factor: 12.310

6.  Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling.

Authors:  Yan Feng; Bruce G Pollock; Robert E Ferrell; Mark A Kimak; Charles F Reynolds; Robert R Bies
Journal:  Br J Clin Pharmacol       Date:  2006-05       Impact factor: 4.335

7.  An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression.

Authors:  Lon S Schneider; J Craig Nelson; Cathryn M Clary; Paul Newhouse; K Ranga Rama Krishnan; Thomas Shiovitz; Karen Weihs
Journal:  Am J Psychiatry       Date:  2003-07       Impact factor: 18.112

8.  Clinical implications of the pharmacology of sertraline.

Authors:  S J Warrington
Journal:  Int Clin Psychopharmacol       Date:  1991-12       Impact factor: 1.659

Review 9.  Sertraline: a review of its use in the management of major depressive disorder in elderly patients.

Authors:  Richard B R Muijsers; Greg L Plosker; Stuart Noble
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

10.  Sertraline pharmacokinetics and dynamics in adolescents.

Authors:  David A Axelson; James M Perel; Boris Birmaher; George R Rudolph; Sharon Nuss; Jeffrey Bridge; David A Brent
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2002-09       Impact factor: 8.829
View more
  2 in total

1.  Pharmacokinetics-pharmacodynamics of sertraline as an antifungal in HIV-infected Ugandans with cryptococcal meningitis.

Authors:  Ali A Alhadab; Joshua Rhein; Lillian Tugume; Abdu Musubire; Darlisha A Williams; Mahsa Abassi; Melanie R Nicol; David B Meya; David R Boulware; Richard C Brundage
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-10-04       Impact factor: 2.745

2.  The role of 5-HT1A receptors in mediating acute negative effects of antidepressants: implications in pediatric depression.

Authors:  K A Rahn; Y-J Cao; C W Hendrix; A I Kaplin
Journal:  Transl Psychiatry       Date:  2015-05-05       Impact factor: 6.222
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.